Cite
MLA Citation
Roy Herbst et al.. “O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A1. http://access.bl.uk/ark:/81055/vdc_100135177555.0x000006